Skip to search formSkip to main contentSkip to account menu

CHF6001

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phosphodiesterase 4 inhibitors attenuate virus‐induced activation of eosinophils from asthmatics without affecting virus binding
Acute respiratory virus infections, such as influenza and RSV, are predominant causes of asthma exacerbations. Eosinophils act as… 
2019
2019
Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
Concentration‐QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase‐4… 
2019
2019
Efficacy and Safety of CHF6001, A Novel Inhaled PDE4 Inhibitor in COPD: The Pioneer Dose Finding Study
  • D. SinghM. A. Nandeuil S. Petruzzelli
  • C32. COPD: TRANSLATIONAL AND MECHANISTIC STUDIES
  • 2019
  • Corpus ID: 202834455
2018
2018
Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001
2016
2016
Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers
Abstract: Chronic obstructive pulmonary disease (COPD) is a multicomponent condition characterized by airway inflammation and… 
2014
2014
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
The anti-inflammatory effect of CHF6001, a novel phosphodiesterase-4 (PDE4) inhibitor delivered via a dry powder inhaler, was… 
2014
2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue
Background : CHF6001 is a novel selective phosphodiesterase type 4 (PDE4) inhibitor designed for inhaled administration and in… 
2014
2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile
Rationale By increasing intracellular cAMP levels, type 4 cyclic nucleotide phosphodiesterases (PDE4) inhibitors elicit a broad… 
2014
2014
Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines
Background Acute respiratory virus infections are common precipitants of asthma exacerbations, with most asthma exacerbations in… 
2014
2014
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window
A strategy to overcome the side effect liabilities of oral phosphodiesterase 4 (PDE4) inhibitors has been to deliver the drugs by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)